The United Kingdom and the United States have concluded a important bilateral deal that will guarantee zero import taxes on British drug products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This move ensures that duties on these vital goods will be held at zero for a duration of 36 months.
This deal is in response to recent statements to significantly raise import taxes on patented drug products, with increases mentioned up to double the cost.
"This arrangement between the Britain strengthens the global environment for cutting-edge drugs and brings much-needed equity to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Significance
Pharmaceuticals constitute one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the largest buyer for large UK drugmakers.
Statistics reveal that in the year to the end of September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that span.
"This deal secures work, stimulates capital expenditure and facilitates the UK to emerge as a international leader for life sciences," a government official commented.
Key UK Commitments
The pact involves several notable commitments from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise total NHS spending on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. In the past, repayments exceeded twenty percent.
Industry Background
This agreement follows a long-running dispute between the sector and the British authorities over medicine costs and approval rates.
This friction were exacerbated by arguments that US patients were charged a premium for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a share of its overall budget over the last ten years.
